Posts Tagged ‘Pharmaceuticals’



Applauding Cautious Optimism from a Big Pharma CEO

December 1st, 2011
Posted by

Recently journalists at WSJ and Xconomy interviewed John Lechleiter, Chairman, President & CEO, of Eli Lilly and Company. When I sat down to read Mr. Lechleiter’s interviews, I was prepared to get up from my desk several times to find something more interesting to do thinking the articles were to be somewhat mind-numbing. My expectations were not based on any preconceived notions about Mr. Lechleiter, but rather that I assumed the focus of the interviews would be lamenting the pharmaceutical industry’s problems. Instead I was encouraged by Lechleiter’s dedication and optimism.
 
It is increasingly easy to criticize big pharma: Fewer truly “new” drugs are developed. It is difficult to understand the economics behind the high costs of certain drugs. After being approved, some drugs go on to be proven ineffective or, sometimes, potentially dangerous.
  Read the rest of this entry »

Tags: , , , , , , , ,
Posted in Our Views | No Comments »





Marrying Targeted Therapies with Companion Diagnostics: The Novartis MDx Model

May 31st, 2011
Posted by

In late 2008, Novartis established its molecular diagnostics unit, to be known as Novartis Molecular Diagnostics (MDx) and to function as an integrated unit within the Novartis Pharmaceuticals Division.  Led by Michael J. Nohaile, Ph.D., Global Head of MDx, the unit is designed to leverage the global pharmaceutical company’s strengths and capabilities in research, development and commercialization to translate identified biomarkers into high-quality diagnostic tests. As Novartis explains via its global website: Novartis MDx strives to become a world leader in developing and commercializing diagnostic tests to optimize patient outcomes and to transform the practice of medicine.
 
Recently, I spoke to Novartis MDx Global Head of Diagnostics Development Michael C. Little, Ph.D., an old colleague of mine from Becton Dickinson and Company, and to Director of Business Development and Licensing Yves Dubaquie, Ph.D., who presented on behalf of Novartis MDx at the Personalized Medicines Partnerships Conference last month. Both gentleman arrived in their current Novartis MDx roles about two years ago and both have impressive industry experience.
  Read the rest of this entry »

Tags: , , , , , , ,
Posted in Our Views | 4 Comments »





Reflecting on J.P. Morgan 29th Annual Healthcare Conference

January 17th, 2011
Posted by

As one of the nearly 8,500 attendees at this year’s J.P. Morgan Healthcare Conference, I’m not alone in recording my observations. However, while the crowds and the climate are still fresh in my mind, I didn’t want to miss the opportunity to share some of my key takeaways. If you were there, please feel free to add your thoughts to the comments section. If you weren’t, let me know if you have any questions about a point I’ve made or curiosity you had about the conference that I haven’t covered.
 
Also, whether you attended or not, you may want to check out the ruminations of TheStreet.com’s Adam Feuerstein who blogged “live” from the conference as well as In Vivo’s Blog on the subject and the prose of the IR Report’s Dominic Jones.
 
My observations:
  Read the rest of this entry »

Tags: , , , , , , ,
Posted in Our Views | No Comments »